Jazz Pharmaceuticals plc (Nasdaq: JAZZ), a global biopharmaceutical company, announced on Wednesday that it has named Philip Johnson as its new executive vice president and chief financial officer, effective 1 March 2024.

Johnson succeeds Renee Gala, who was promoted to the position of president and chief operating officer in October 2023. In the new role, Johnson will manage financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also manage the firm's investor relations and corporate development functions.

Johnson has more than 35 years of financial experience. Most recently, he has headed Eli Lilly and Company's treasury and investor relations operations as group vice president of finance.

.

(C) 2024 M2 COMMUNICATIONS, source M2 PressWIRE